Malinka Walaliyadde Net Worth: CEO and Co-founder of AKASA GeneAI Healthcare

Malinka Walaliyadde Net Worth: Malinka Walaliyadde is the co-founder and chief executive officer of (CEO) of AKASA GeneAI Healthcare. He co-founded the healthcare company in 2019 with Varun Ganapathi, Ben Beadle-Ryby, and Andy Atwal. Previously it was called AlphaHealth, before the name changed to its current one. 

AKASA is a healthcare technology company that specializes in using artificial intelligence (AI) to improve the revenue cycle for healthcare providers. 

Their platform leverages generative AI and large language models trained on vast amounts of clinical and financial data to automate tasks, streamline processes, and enhance decision-making. 

In 2018, Malinka Walaliyadde was included in Forbes Magazine’s list of 30 Under 30 in the Venture Capital category. Before founding AKASA Healthcare, Walaliyadde worked at Andreessen Horowitz, Corning Life Sciences, Counsyl, and Deloitte. 

This article will look into Malinka Walaliyadde net worth, education, career, and more. 

Evan Reiser Net Worth – CEO & Co-Founder of Abnormal Security

Malinka Walaliyadde Net Worth

Unfortunately, there is no information available on Malinka Walaliyadde’s net worth. We will update this section as soon as we come across any concrete data on Walaliyadde’s wealth.

However, it is worth noting that as the co-founder and chief executive officer of AKASA, Malinka Walaliyadde’s net worth will be closely tied to how well the company performs. 

Education

Malinka Walaliyadde earned a Bachelor’s degree in Materials Engineering (Major) and Biomedical Engineering (Minor). He graduated cum laude with honors from Cornell University. 

Christian Klein Net Worth – CEO of SAP

Career

Malinka Walaliyadde began his career in 2009 as a Co-founder and President of ECaFT, a student business focused on recruitment, connecting over 2,000 students with 100+ employers. Simultaneously, he co-founded Cornell University Genetically Engineered Machines (CU GEM), a student research lab, where he helped the team compete in the international genetic engineering competition (iGEM) held at MIT. His team, combining molecular biology, software, and hardware, won a gold medal for their innovative projects.

In 2010, Malinka took on the role of Engineering Co-op at Corning Incorporated’s Life Sciences division. Over two co-op terms, he worked on software and hardware for a drug discovery platform, writing software that increased data availability and sped up data analysis, reducing processing time from minutes to seconds. He also co-led a team for the Cornell Innovation Competition from 2010 to 2011, where he and his team won a $15,000 first-place prize for developing a soil testing system designed to cut fertilizer costs and increase crop yield for the agricultural sector.

In 2012, he joined Counsyl as a Product Analytics intern, where he developed a statistical model for genetic inheritance to calculate operational risk and assist in R&D. He reported directly to the CTO, providing valuable insights that supported the company’s new product offerings. Shortly after, he worked at Deloitte as an Analyst in healthcare and financial services, gaining industry experience in these critical sectors.

In 2013, he was a founding team member of 1729, a startup led by Balaji Srinivasan, focusing on creating opportunities for global talent. Building on his experience, Malinka joined Andreessen Horowitz (a16z) in 2014 as a Partner. He was instrumental in establishing the firm’s healthcare investment team, which grew to manage $1.4 billion in assets. Over his four years there, he worked on nearly 20 investments across healthcare technology, providers, payers, and biotech, amounting to $250 million.

During his time at a16z, Malinka also held several board attendee positions. He served at Omada Health from 2015 to 2018, Apeel Sciences from 2016 to 2018, and PatientPing from 2016 to 2018, where he contributed his expertise in healthcare and technology investments.

In January 2019, Malinka co-founded and became CEO of AKASA (formerly Alpha Health) in the San Francisco Bay Area. AKASA’s mission is to reduce financial complexity in healthcare by pioneering Unified Automation for healthcare revenue cycle management. The company integrates data, people, and machine learning technology to streamline healthcare financial processes, helping health systems become better stewards of the healthcare dollar.

Latest Updates

Recently, AKASA GeneAI Healthcare raised $60 million in a Series B Funding Round. With this funding, AKASA is planning to amp up its operations to meet the increasing consumer demands, hire more staff, and invest more in marketing to boost the company’s image. The funding round was led by BOND, with participating from Andreessen Horowitz (a16z) and Costanoa Ventures. 

CEO Malinka Walaliyadde said, “We are incredibly optimistic about the coming year and our long-term opportunity to serve as a catalyst for improving efficiency in our healthcare system at scale. We remain focused on our mission to remedy financial complexity in order to reduce healthcare costs for everyone.” 

Dheeraj Pandey Net Worth – Founder of DevRev

FREQUENTLY ASKED QUESTIONS

Who is the CEO of Akasa health care?

The CEO of Akasa Healthcare is Malinka Walaliyadde. He co-founded the healthcare company, formerly known as AlphaHealth, in 2019 with Varun Ganapathi, Ben Beadle-Ryby, and Andy Atwal. 

Who is Malinka Walaliyadde?

Malinka Walaliyadde is the co-founder and chief executive officer of (CEO) of AKASA GeneAI Healthcare. He co-founded the healthcare company in 2019.